The North America peptide therapeutics CDMO market size was estimated at USD 1.03 billion in 2025 and is projected to be worth around USD 2.72 billion by 2035, expanding at a CAGR of 10.20% from 2026 to 2035. Growing due to increasing outsourcing of drug development and strong demand for biologics and advanced therapies.

North America Peptide Therapeutics CDMO Market Statical Scope

Increased outsourcing of biologics , cell and gene therapies, and sterile injectable manufacturing by pharmaceutical companies is driving the growth of the North American therapeutics CDMO market; companies are adopting integrated CDMO services to lower operating costs and expedite drug commercialization timelines; increasing investments in high-potency API facilities and advanced manufacturing technologies are strengthening regional production capabilities; and the adoption of AI-driven drug development and automated production systems is improving manufacturing efficiency and scalability. To lower operating costs and shorten the time it takes for drugs to be commercialized, businesses are increasingly implementing integrated CDMO services. Regional production capabilities are further strengthened by increasing investments in innovative manufacturing technologies and high-potency API facilities. Additionally, the use of automated production systems and AI-driven medication development is increasing the scalability and efficiency of manufacturing.

Growing outsourcing of drug development, growing demand for biologics and specialty therapeutics, the presence of large pharmaceutical and biotechnology companies supporting ongoing investments in advanced manufacturing technologies, growing clinical trials activities, and an increasing emphasis on precision medicine are all driving the therapeutics CDMO market in North America. The existence of significant biotechnology and pharmaceutical firms encourages ongoing investments in cutting-edge production methods. The need for adaptable CDMO services is also being accelerated by an increase in clinical trial activities and a growing emphasis on precision medicine .

North America Peptide Therapeutics CDMO Market Share, By Synthesis Method, 2025 (%)

• Solid-Phase Peptide Synthesis (SPPS): Solid-phase peptide synthesis (SPPS) segment dominated the market in 2025 with market share of 34%, driven by its extensive use in the production of therapeutics peptides scalability for commercial manufacturing and high efficiency in creating complex peptide chains. CDMOs greatly favor this method because it allows for faster synthesis cycles and higher purity levels.
• Liquid-Phase Peptide Synthesis (LPPS): Liquid-phase synthesis (LPPS) segment was the fastest growing in the market with a share of 11% driven by improvements in purification technologies and the growing need for large scale reasonably priced peptide production its improved process economics and suitability for shorter peptide sequences contributed to the markets growth.

North America Peptide Therapeutics CDMO Market Share, By Service Type, 2025 (%)

• API development & manufacturing: API development & manufacturing segment dominated the market in 2025 with a market share of 24% driven by pharmaceutical companies growing outsourcing efforts and the growing need for peptide-based drug protection. The expansion of the segment was also aided by rising investments in commercial scale peptide manufacturing facilities.
• Process development & optimization: Process development & optimization motivated by the need to ensure regulatory compliance, lower production costs, and improve manufacturing efficiency. Adoption was further accelerated by a greater emphasis on scalable peptide synthesis methods and yield enhancement.

North America Peptide Therapeutics CDMO Market Share, By Peptide Type, 2025 (%)

• Generic peptide: Generic peptide segment was the fastest growing in the market with a share of 19% driven by the growing demand for less expansive therapeutic alternatives and the growing availability of generic peptide medications. Market expansion was further aided by advantageous regulatory pathways.
• Innovative/Novel Peptides: Innovative/novel peptides segment dominated the market in 2025 with a market share of 22% fueled by growing research partnerships and increased investments in cutting edge peptide treatments. Expanding the segment was further reinforced by the growing emphasis on personalized medicine.

North America Peptide Therapeutics CDMO Market Share, By Application Area, 2025 (%)

• Oncology & Cancer Treatment: Oncology & cancer treatment segment dominated the market in 2025 with a market share of 24% driven by the growing incidence of cancer and the advancement of targeted therapies based on peptides. Increasing the number of oncology clinical trials helped the segment grow even more.
• Diabetes & Metabolic Disorders: Diabetes & metabolic disorders segment was the fastest growing in the market with a share of 18%, driven by rising incidence of obesity related disorders and the growing use of peptide therapies for the treatment of metabolic diseases. Growing demand for GLP1 analogs contributed to the expansion as well.

North America Peptide Therapeutics CDMO Market Share, By Scale of Operation, 2025 (%)

• Research & Development Scale: Research & development scale segment dominated the market in 2025 with a market share of 20%, driven by rising investments in early-stage therapeutic research and an increase in peptide drug discovery activities. Demand was further bolstered by growing academic and biotech partnerships.
• Clinical Trial Manufacturing: Clinical trial manufacturing segment was the fastest growing in the market with a share of 18% driven by increasing number of peptide therapeutics entering clinical evaluation and rising outsourcing trends among pharmaceutical companies.

North America Peptide Therapeutics CDMO Market Share, By End User Type, 2025 (%)

• Large Pharmaceutical Companies: The large pharmaceutical companies segment dominated the market in 2025 with a market share of 28%, fueled by strategic outsourcing alliance with CDMOs and growing demand for large scale peptide production. Segment of dominance was further aided by significant R&D investments.
• Biotechnology Companies: The Biotechnology companies segment was the fastest growing in the market with a share of 24% driven by rising peptide innovation. Increasing venture funding. And expanding biotech research activities across Europe.

Competitive Landscape

The North America therapeutics CDMO market is highly competitive with the presence of major pharmaceutical manufacturing companies focusing on biologics, cell and gene therapy, and sterile injectable production. Companies are expanding manufacturing capacities and investing in advanced technologies to strengthen their market position. Strategic collaborations with biotech firms and increasing acquisitions are also intensifying competition across the region. Major companies operating in the market include Thermo Fisher Scientific, Catalent, Charles River Laboratories, Pfizer CentreOne, Curia Global, and Resilience.

Segments Covered in the Report

By Synthesis Method

• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Hybrid/Mixed-Phase Synthesis
• Recombinant Peptide Production
• Chemical Synthesis Methods
• Enzymatic Synthesis Approaches
• Fragment Condensation Techniques
• Convergent Synthesis Strategies

By Service Type

• API Development & Manufacturing
• Process Development & Optimization
• Analytical Method Development & Validation
• Regulatory Affairs & CMC Support
• Formulation Development
• Fill-Finish & Packaging Services
• Quality Control & Assurance
• Clinical Trial Material Manufacturing
• Commercial Manufacturing
• Technology Transfer Services

By Peptide Type

• Generic Peptides
• Innovative/Novel Peptides
• Modified Peptides (PEGylated, Lipidated)
• Cyclic Peptides
• Stapled Peptides
• Peptide-Drug Conjugates (PDCs)
• Antimicrobial Peptides
• Hormonal Peptides
• Therapeutic Proteins & Peptides
• Cosmetic & Nutraceutical Peptides

By Application Area

• Oncology & Cancer Treatment
• Diabetes & Metabolic Disorders
• Cardiovascular Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Autoimmune & Inflammatory Conditions
• Hormonal Therapies
• Pain Management
• Dermatology & Cosmetics
• Gastrointestinal Disorders

By Scale of Operation

• Research & Development Scale
• Clinical Trial Manufacturing
• Pilot Scale Production
• Commercial Scale Manufacturing
• Large-Scale Industrial Production
• Custom Small Batch Production

By End-User Type

• Large Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutions
• Government Research Organizations
• Clinical Research Organizations (CROs)
• Specialty Pharmaceutical Companies
• Generic Drug Manufacturers
• Cosmetic & Nutraceutical Companies